EX-12
 

Exhibit 12

PFIZER INC AND SUBSIDIARY COMPANIES
COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES

                                         
    Year Ended December 31,  
(in millions, except ratios)   2004     2003     2002     2001     2000  
 
Determination of Earnings:
                                       
Income from continuing operations before provision for taxes on income, minority interests and cumulative effect of change in accounting principles
  $ 14,007     $ 3,246     $ 11,766     $ 9,963     $ 5,471  
Less:
                                       
Minority interests
    10       3       6       14       13  
 
                             
Income adjusted for minority interests
    13,997       3,243       11,760       9,949       5,458  
Add:
                                       
Fixed charges
    595       491       365       359       478  
 
                             
Total earnings as defined
  $ 14,592     $ 3,734     $ 12,125     $ 10,308     $ 5,936  
 
                             
Fixed charges:
                                       
Interest expense (a)
  $ 347     $ 270     $ 251     $ 266     $ 381  
Preferred stock dividends (b)
    12       10                    
Rents (c)
    236       211       114       93       97  
 
                             
Fixed charges
    595       491       365       359       478  
Capitalized interest
    12       20       28       56       46  
 
                             
Total fixed charges
  $ 607     $ 511     $ 393     $ 415     $ 524  
 
                             
 
                                       
Ratio of earnings to fixed charges
    24.0       7.3       30.9       24.8       11.3  
 
                             


All financial information reflects the following as discontinued operations for 2004 and 2003: our in-vitro allergy and autoimmune diagnostics testing, surgical ophthalmics and certain European generics businesses as well as, for 2004, 2003, 2002, 2001 and 2000 certain non-core consumer healthcare product lines (primarily marketed in Europe).

All financial information reflects the following as discontinued operations for 2003, 2002, 2001 and 2000: our confectionery, shaving and fish-care products businesses as well as the Estrostep, Loestrin and femhrt women’s health product lines.

(a)   Interest expense includes amortization of debt premium, discount and expenses.
 
(b)   Preferred stock dividends are from our Series A convertible perpetual preferred stock held by an Employee Stock Ownership Plan assumed in connection with our acquisition of Pharmacia.
 
(c)   Rents included in the computation consist of one-third of rental expense which we believe to be a conservative estimate of an interest factor in our leases, which are not material.